Skip to main content

CNTO1275CRD3008 A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease

NCT03782376

A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease

Associated Conditions

Colon

Principal Investigator

Sponsor

Janssen Research & Development

The purpose of this study is to see if an additional intravenous (IV) dose of ustekinumab (sold as STELARA) is safe and useful for helping patients with moderately to severely active Crohn’s Disease to regain response to ustekinumab for the treatment of their disease.